Article info

Download PDFPDF
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

Authors

  1. Correspondence to Dr Daniel J Wallace, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048-0750, USA; danielwallac{at}gmail.com
View Full Text

Citation

Wallace DJ, Figueras F, Wegener WA, et al
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

Publication history

  • Received December 31, 2020
  • Revised January 25, 2021
  • Accepted February 10, 2021
  • First published February 22, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.